Clinical Trials Browser

Withdrawn × Carcinoma, Non-Small-Cell Lung × Magnetic Resonance Spectroscopy × Clear all

NCT05840770 2025-05-26

Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06427369 2024-09-27

An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer

Phase 1 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT05935774 2023-08-25

OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02607423 2023-05-25

Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT00471835 2017-01-19

Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer

Phase 1/2 Withdrawn

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01314677 2012-06-29

Fludeoxyglucose F 18 PET/CT Scans in Predicting Therapy Response in Patients With Stage IIIA Non-Small Cell Lung Cancer Undergoing Chemoradiation

Phase NA Withdrawn

Carcinoma, Non-Small-Cell Lung